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Evidence from human studies suggests that angiogenesis commences during the pre-malignant stages of cancer. Inhibiting
angiogenesis may, therefore, be of potential value in preventing progression to invasive cancer. Understanding the mechanisms
inducing angiogenesis in these lesions and identification of those important in human tumourigenesis are necessary to develop
translational strategies that will help realise the goal of angioprevention.
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Pre-malignant conditions are clinically recognisable lesions that
are strongly associated with the development of malignant
neoplasia. Pre-malignant lesions are defined by the epidemiologi-
cal observation that patients with such lesions have an increased
risk of cancer, and conversely, patients with cancer of a specific
organ also display a high incidence of pre-malignant conditions
(Peckham et al, 1995). It is therefore important to detect these
precursor lesions and to stratify according to the risk of cancer
development, thus allowing the identification of high-risk groups
and for programmes of education, screening and prophylactic
therapy to be developed (Kumar et al, 2005).
Pre-malignant lesions have been identified in almost all
epithelial organs, and a distinct histological state termed dysplasia
has been described (Table 1). This implies a disorderly but non-
neoplastic proliferation, with loss of cellular uniformity and
architectural organisation. Mild-to-moderate changes that do not
involve the entire epithelium may be reversible with the removal
of putative inciting causes. In contrast, carcinoma in situ, a lesion
in which dysplastic changes are marked and involve the entire
thickness of the epithelium, is considered to be a pre-invasive stage
of cancer that possesses all the morphological features of cancer,
except evidence of invasion beyond the basement membrane
(Kumar et al, 2005).
Angiogenesis, the growth of new vessels from the existing
vasculature, plays an essential role in tumour progression,
providing nutrients and growth factors, in addition to aiding
tumour cell dissemination (Hanahan and Folkman, 1996).
Angiogenesis requires the release of growth factors mitogenic to
endothelium, and the process is dependent on the net balance of
angiogenic and antiangiogenic factors. The progression of an
avascular tumour to the vascularised angiogenic phenotype is
termed the ‘angiogenic switch’ (Folkman et al, 1989) and is likely
to occur by multiple small steps resulting in a gradual increase in
angiogenic potential, as the normal tissue acquires neoplastic
features transforming initially to a pre-invasive cancer, with a
subsequent progression to an invasive tumour in some cases.
There is increasing evidence that the angiogenic process com-
mences in the pre-malignant stages of most cancers based on
experimental as well as clinical observations that challenge the
previously held paradigm that malignant tumours induce angio-
genesis at a volume of 1–2mm
3 (Gimbrone et al, 1972). There is
also evidence that therapeutic interventions, which prevent
angiogenesis, decrease the aggressiveness of malignancy; therefore,
this approach may prevent or delay the progression of pre-
malignant conditions to frank malignancy (Albini et al, 2007). In
addition, evidence of increased angiogenesis in pre-malignant
lesions may serve as a surrogate marker for tumour development,
as the majority do not progress to malignant disease. Identification
of the stage in the spectrum of disease, when the shift in the
balance of factors influencing angiogenesis occurs, and the factors/
mechanisms responsible for this shift is therefore important in
developing strategies to prevent the progression of pre-malignant
lesions to malignant tumours.
Although there are myriad pro- and antiangiogenic growth
factors, based on knowledge gained from investigations of
angiogenesis in malignant tumours, the following factors have
been studied in human pre-malignant lesions. The most potent
angiogenic growth factors belong to the vascular endothelial
growth factor (VEGF) family. Vascular endothelial growth factor-A
(commonly referred to as VEGF) is the most abundant family
member acting as a specific mitogen for endothelial cells in vitro
and as an angiogenic molecule in vivo (Ferrara et al, 2003). The
primary regulator of VEGF secretion is the hypoxic microenviron-
ment, which is mediated by the transcription factor hypoxia-
inducible factor 1-a (HIF-1a). Under hypoxic conditions, HIF-1a
accumulates in the cytoplasm and forms a heterodimer with
HIF-1b. This, in turn, facilitates nuclear translocation of HIF-1a,
where it initiates the transcription of genes involved in various
cellular responses to hypoxia (Pugh and Ratcliffe, 2003). The
Revised 9 July 2008; accepted 23 September 2008; published online 21
October 2008
*Correspondence: Professor MWR Reed, Academic Surgical Oncology
Unit, K Floor, School of Medicine and Biomedical Sciences, University of
Sheffield, Beech Hill Road, Sheffield S10 2RX, UK;
E-mail: m.w.reed@sheffield.ac.uk
British Journal of Cancer (2008) 99, 1961–1966
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $32.00
www.bjcancer.comactions of VEGF are mediated by a family of closely related tyrosine
kinase receptors consisting of three members termed VEGFR-1,
VEGFR-2 and VEGFR-3. Vascular endothelial growth factor
receptor-2 is the principal pro-angiogenic receptor and mediates
the majority of the downstream effects of VEGF-A (Ferrara et al,
2003). Thymidine phosphorylase (TP), an intracellular enzyme
exhibiting angiogenic activity, stimulates endothelial cell prolifera-
tion and migration (Ishikawa et al, 1989). It also confers resistance
to hypoxia-induced apoptosis. Matrix metalloproteinases (MMPs)
facilitate angiogenesis by degrading the basement membrane and
the ECM, which in addition to facilitating capillary formation also
releases growth factors bound in the stroma (Folgueras et al, 2004).
Discussion of all the growth factors and inhibitors involved in the
phenomenon of angiogenesis is beyond the scope of this review.
This review focuses on the current available evidence supporting the
concept of angiogenesis in human pre-malignant lesions and the
putative mechanisms regulating this phenomenon.
EVIDENCE FOR INCREASED ANGIOGENESIS IN
HUMAN PRE-MALIGNANT CONDITIONS
Experimental tumours less than 1mm
3 are in general avascular
and grow slowly due to limitations imposed by the rate of diffusion
of oxygen and nutrients. This was based on the observations that
tumours grown in isolated avascular areas, such as the aqueous
chamber of the eye (where blood vessels could not proliferate),
expanded only to a size of 1mm
3, but after implantation into the
iris, which is highly vascular, neovascularisation was induced and
the tumour demonstrated rapid growth (Gimbrone et al, 1972).
However, this paradigm was challenged by the RIP-TAG transgenic
murine model of islet cell tumorigenesis (Hanahan, 1985). The
mice express the large T antigen in their islet cells at birth and
express the SV40 antigen under the control of the insulin gene
promoter, resulting in a sequential development of tumours in
the islets over a period of 12–14 weeks. Tumour development
proceeds in stages; initially, approximately 50% of the islets
become hyperproliferative with a subset (25%) subsequently
acquiring the ability to induce angiogenesis, approximately
15–20% of which develop into benign and invasive tumours. It
is evident from this model that angiogenesis commences well
before the emergence of an invasive malignant phenotype
(Folkman et al, 1989). Subsequently, considerable evidence has
accumulated in favour of this concept from studies in human pre-
malignant lesions, the majority of which have quantified
angiogenesis using the surrogate measure of microvessel density
(MVD). This is the mean microvessel count, obtained using a
limited number of fields, subjectively selected and representing the
most vascularised areas termed as ‘hot spots’ (Fox and Harris,
2004). The most commonly used antigens to characterise
microvessels immunohistologically are Factor VIII, CD31 and
CD34. It is now also possible to discriminate between newly
formed immature and established mature vessels using CD105
(Fox and Harris, 2004). In addition, the expression of angiogenic
growth factors by pre-malignant lesions is also considered to be an
indicator of angiogenic activity. The following summarise the
evidence for angiogenesis from individual human organs.
Skin
Both epithelial and melanocytic pre-malignant lesions have been
investigated for angiogenic activity. Immunohistochemical analy-
sis of actinic keratoses and Bowen’s disease from 35 individuals
demonstrated both increased MVD and endothelial proliferation
rate. Both parameters increase significantly at each disease stage,
suggesting that angiogenic activity is increased early in the
development of dermal squamous cell carcinomas (SCCs) (Nijsten
et al, 2004). Pre-malignant lesions of the melanocyte lineage also
demonstrate significantly increased MVD between benign naevi
and dysplastic nodules (Barnhill et al, 1992).
Respiratory tract
Angiogenesis has been identified in laryngeal leukoplakia, with
MVD increasing significantly between normal epithelium and
dysplasia and between dysplasia and carcinoma (Franchi et al,
2002). In bronchial pre-malignant lesions, a progressive increase in
MVD from hyperplastic/metaplastic lesion to dysplasia or in situ
carcinoma has been demonstrated. Vascular endothelial growth
factor mRNA and protein expression parallel the increased MVD
in these lesions, with VEGF expression predominantly in the
bronchial epithelium (Merrick et al, 2005).
Table 1 Pre-malignant lesions and risk of their transformation into corresponding malignancies (compiled from Peckham et al (1995), except where
indicated)
Organ Lesion Cancer Overall lifetime risk of transformation
Skin Actinic keratoses SCC 10%
Bowen’s disease SCC Considered to be superficial SCC, 100 % risk of progression
Dysplastic nodule Malignant melanoma Lifetime risk 100%
Larynx Leukoplakia SCC 5–10%
Bronchus Bronchial dysplasia SCC 10–40% (Merrick et al, 2005)
Oral cavity Leukoplakia SCC 5–10%
Oesophagus Barrett’s dysplasia Adenocarcinoma 10%
Epithelial dysplasia SCC 90% of patients with tylosis (genetic disorder characterised by
hyperkeratosis of palms and soles) progress to SCC
Stomach Chronic gastritis Adenocarcinoma 2–4%
Colon Adenoma Adenocarcinoma 10–15%
Anal canal Anal intraepithelial neoplasia SCC 5% (Mullerat et al, 2003)
Liver Dysplastic nodule Hepatocellular carcinoma Unknown
Vulva Vulvar intraepithelial neoplasia SCC 5% of treated women progress to cancer, 90% untreated
women progress (Raspollini et al, 2007)
Cervix Cervical intraepithelial neoplasia SCC 30–50% (Tjalma et al, 1999)
Prostate Prostatic intraepithelial neoplasia Adenocarcinoma High-grade PIN is a marker for a high risk of concomitant or
later (33–100%) carcinoma (Sinha et al, 2004)
Breast Usual hyperplasia Adenocarcinoma Relative risk increased 1.5- to 2-fold (Arpino et al, 2005)
Atypical hyperplasia Adenocarcinoma Relative risk increased four-fold (Arpino et al, 2005)
Ductal carcinoma in situ Adenocarcinoma Relative risk increased 8- to 10-fold (Arpino et al, 2005)
SCC¼squamous cell carcinoma.
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Studies of oral pre-malignant tissue demonstrated a significant
increase in MVD with progression from normal epithelium to
invasive cancer (Carlile et al, 2001). In a large series of Barrett’s
oesophagus and associated adenocarcinoma, angiogenesis was
markedly increased in pre-malignant lesions, which correlated
with VEGF expression. Vascular endothelial growth factor expres-
sion was elevated in epithelial cells with strong VEGFR-2
expression on associated vessels (Auvinen et al, 2002). Evidence
of enhanced angiogenesis was also demonstrated in precursor
lesions of oesophageal SCC accompanied by elevated VEGF and TP
levels (Kitadai et al, 2004). Increased CD34 microvessel count and
VEGF mRNA and protein expression was demonstrated in
Helicobacter pylori-associated gastritis (Tuccillo et al, 2005).
Vascular endothelial growth factor expression and inducible nitric
oxide synthase were also elevated in chronic atrophic gastritis as
well as in metaplastic and dysplastic areas before the onset of
gastric cancer (Feng et al, 2002).
Investigations in our unit quantifying angiogenesis in the
colorectal adenoma-carcinoma sequence using immunohisto-
chemical staining for CD31 antigen suggest that a significant
increase in MVD is induced with the onset of dysplasia, parallelled
by a significant increase in VEGF expression at the same stage of
progression (Staton et al, 2007). Microvessel density and VEGF
expression also increase in a linear manner with the progression of
transformation in anal intraepithelial neoplasia, the precursor of
anal SCC (Mullerat et al, 2003). Angiogenesis, as defined by the
extent of sinusoidal capillarisation detected by CD34 antibodies,
increases with progression towards hepatocellular carcinoma
(HCC) commencing at the low-grade dysplastic nodule stage with
a concomitant increase in VEGF expression (Park et al, 2000).
Genitourinary tract
Studies of vulvar intraepithelial neoplasia (VIN), the precursor of
vulvar carcinoma, demonstrate a significant increase in MVD with
increasing grade, which correlates with VEGF expression. Micro-
vessel density alone is also a valuable tool in identifying potential
progression to SCC in some cases of VIN III (Bamberger and
Perrett, 2002). Several studies have concluded that there is a
progressive increase in MVD from normal epithelium to SCC
through cervical intraepithelial neoplasia, with some studies also
demonstrating a significant correlation between MVD and VEGF
expression (Dobbs et al, 1997; Tjalma et al, 1999). Thymidine
phosphorylase expression also increases with lesion severity, but
this does not correlate with MVD (Dobbs et al, 2000). In a large
proportion of high-grade prostatic intraepithelial neoplasia, MVD
is increased compared with normal tissue, which predicts
concomitant prostatic carcinoma (Sinha et al, 2004).
Breast
Although ductal carcinoma in situ (DCIS) has been studied
extensively, increased vascularisation and VEGF expression has also
been identified in both usual and atypical hyperplasia compared with
normal ductal epithelium lesions thought to precede DCIS (Bos et al,
2001). Ductal carcinoma in situ lesions exhibit two patterns of
angiogenesis, an increased stromal MVD and a periductal cuff of
microvessels surrounding the basement membrane of the ducts. The
tumour cells also expressed high levels of VEGF mRNA and VEGF
protein, and there is increased VEGF receptor expression on the
endothelial cells surrounding the tumours (Guidi et al, 1997).
Overall, evidence from human studies supports experimental
observations from murine models, suggesting that initiation of
angiogenesis occurs in the pre-malignant stages of cancer
development. This is supported by the demonstration of the onset
of angiogenesis, as determined by MVD, which precedes invasive
cancer development in all the precursors of solid human cancers
studied to date. There is also evidence supporting the premise that
increased production of angiogenic growth factors by the tumour
cells is responsible for the increased vascularisation of pre-
malignant lesions. Although there is no consensus regarding
increased MVD as a predictor of progression to malignancy,
angiogenesis appears to be initiated during the pre-malignant
stages and that progression to invasive cancer may therefore, at
least in part, be facilitated by the increased supply of nutrients and
oxygen provided by the increased vascular supply.
UNDERLYING MECHANISMS INITIATING
ANGIOGENESIS IN PRE-INVASIVE LESIONS
Substantial insights have been gained into the angiogenic
mechanisms involved in malignant tumours. The subsequently
developed antiangiogenic therapies demonstrated efficacy in the
pre-clinical setting, and this has now been translated into clinical
practice. Although it may be presumed that the same biochemical
and physiological mechanisms are involved in the induction of
angiogenesis in pre-malignant lesions, there is currently limited
evidence to support this assumption. This could have been due to
the paucity of experimental cell lines and animal models that are
representatives of pre-malignant disease. Appropriate models of
pre-malignant lesions are now being developed, which will assist in
further understanding of the mechanisms involved (Heppner and
Wolman, 1999; Tanaka et al, 2006). A combination of data from
human tissue studies and investigations on experimental animal
models has increased our understanding of some aspects of
angiogenesis initiation in these lesions.
Hypoxia-mediated angiogenesis
Overexpression of HIF-1a has been demonstrated in pre-malignant
lesions of the breast, oesophagus and prostate (Bos et al, 2001;
Griffiths et al, 2007), with HIF-1a levels correlating with VEGF
expression and MVD in all the three organs. However, the lesions
have no obvious areas of necrosis, suggesting that the upregulation
of HIF-1a may be due to non-hypoxic mechanisms. This apparent
paradox has been investigated in pre-malignant hepatic lesions
(Tanaka et al, 2006). Oxygen tension was measured in vivo within
murine pre-neoplastic hepatic lesions, which were shown to
overexpress HIF-1a and its transcriptional targets such as VEGF
and glut-1. Oxygen tension within these lesions was not different
from that of normal liver tissue. However, the PI3K/Akt pathway,
which can upregulate HIF-1a expression, was activated in these
lesions and may be responsible for the non-hypoxic upregulation
of HIF-1a expression (Tanaka et al, 2006). The activity of cellular
kinases has also been found to be responsible for increased HIF-1a
activity in hepatitis C virus (HCV)-infected hepatic cells. Hepatitis
C virus, an RNA virus, promotes the development of chronic
hepatitis and subsequent HCC (Nasimuzzaman et al, 2007). These
observations suggest that genetic changes promoting carcino-
genesis can result in an aberrant activation of hypoxic signalling in
the cells of pre-malignant lesions under normoxic conditions.
Inflammatory mediator-promoted angiogenesis
Inflammation has been known for many years to be an initiator
and promoter of carcinogenesis and angiogenesis. There is now
convincing evidence that inflammatory mediators are critical
for the stromal changes supporting the development of cancer
(Mantovani et al, 2008). Upregulation of cylooxygenase-2 (COX-2)
has been widely reported in pre-malignant lesions and corre-
lates with angiogenesis (Raspollini et al, 2007). Macrophage
infiltration of pre-malignant lesions also correlates with neo-
plastic progression and angiogenesis (Mazibrada et al, 2008). These
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source of several inflammatory mediators that promote angiogenesis
including TNF-a, MMPs, COX-2 and chemokines. Our own in vitro
investigations into the involvement of macrophages in tumour
angiogenesis indicate that the infiltration of macrophages into breast
cancer cell spheroids resulted in at least a three-fold upregulation in
the release of VEGF when compared with spheroids composed only
of tumour cells. The angiogenic response measured around the
spheroids, 3 days after in vivo implantation into dorsal skinfold
chambers, was significantly greater in the spheroids infiltrated with
macrophages (Bingle et al, 2006). Evidence for similar role in pre-
malignant lesions is provided by a transgenic mouse model of breast
carcinogenesis in which inhibition of macrophage infiltration into
tumours delayed the angiogenic switch whereas pre-mature induction
of macrophage infiltration into pre-malignant lesions promoted an
early onset of angiogenic switch (Lin et al, 2006). The transcription
factor nuclear factor-kappa B (NF-kB), a key controller of the
inflammatory process, is activated by a large number of stimuli
including microbial pathogens, tissue injury and necrosis among
several others (Karin, 2006). Activated NF-kB plays a critical role in
inflammation-driven tumour progression as it influences multiple
processes such as cell-cycle control, apoptosis, stromal protease
production and angiogenesis in addition to the release of inflamma-
tory mediators including interleukin-8 (IL-8), which promotes
tubular morphogenesis of endothelial cells (Shono et al, 1996). It
also acts as a chemoattractant, leading to the recruitment of
monocytes, neutrophils and T lymphocytes to tumour sites, which
release MMPs and chemokines stimulating angiogenesis. Increased
activation of NF-kB may be secondary to abnormal upstream
pathways regulated by oncogenic tyrosine kinases such as the Ras/
MEK/ERK pathway (Mantovani et al, 2008). In addition, there is
evidence that HIF-1a and NF-kB may act synergistically, further
increasing angiogenesis (Scortegagna et al, 2008).
Oncogene-mediated angiogenesis
Recently, evidence has accumulated that certain oncogenes can
directly induce angiogenesis. These include the RAS and MYC,
which are implicated in the development of multiple cancers. Ras
proteins are a family of signal-transducing G proteins. Ras
activates the MAP kinase pathway, which in turn targets nuclear
transcription factors promoting mitogenesis (Shaw and Cantley,
2006). Nuclear factor-kB is one of the proteins whose expression
is increased by this process and can act as a promoter of
angiogenesis. The MYC proto-oncogene is expressed in virtually all
eukaryotic cells and belongs to a group of genes that are rapidly
induced when quiescent cells receive a signal to divide. In a mouse
transgenic model of Myc-dependent b-cell carcinogenesis, the
onset of endothelial cell proliferation was noted to begin shortly
after Myc-induced cell cycle entry of pancreatic b cells. Subsequent
endothelial proliferation was not caused by local tissue hypoxia
but through the release of pre-existing sequestered VEGF from the
ECM by MMPs mediated by the production and release of the pro-
inflammatory cytokine IL-1b (Shchors et al, 2006).
The tumour suppressor p53 acts as a suppressor of angiogenesis
by regulating the production of thrombospondin-1, a potent
angioinhibitor (Dameron et al, 1994). Decreased p53 activity
correlates with increased expression of VEGF and angiogenesis in
bronchial dysplasia and CIN (Fontanini et al, 1999; Lee et al, 2003).
Phosphatase and Tensin homologue (PTEN) is a tumour
suppressor gene that induces cell cycle arrest and apoptosis. Loss
of PTEN protein occurs during pre-malignant stages of endo-
metrial carcinoma (Mutter, 2002). PTEN also acts as an inhibitor of
the PI3K/Akt pathway that regulates the synthesis of HIF-1a, and
therefore loss of PTEN activity can lead to the promotion of
angiogenesis (Lee et al, 2005).
This phenomenon has also been observed during human viral
oncogenesis. Infection with the oncogenic human papilloma virus is
an initiating factor in the carcinogenesis of uterine cervix. The high-
risk oncoproteins, E6 and E7, are necessary for the immortalisation
and transformation of cervical keratinocytes. The oncoprotein E6
binds to p53 protein, whereas E7 binds to the tumour suppressor RB
(retinoblastoma gene product) and induces their degradation. In
addition, the overexpression of these proteins in cervical cancer cells
increases HIF-1a and VEGF expression, thus potentially promoting
angiogenesis in cervical neoplasia (Tang et al, 2007). Hepatitis C
virus infection is an important cause of HCC, and in HCV-infected
hepatic cells, it has been shown that HIF-1a is stabilised under
normoxic conditions, leading to an increased production of VEGF
(Nasimuzzaman et al,2 0 0 7 ) .
In summary, the angiogenic switch involves a reprogramming
of the cellular transcription profile, with pro-angiogenic factors
predominating over antiangiogenic factors, resulting in an angio-
genic phenotype. The examples detailed reflect the way in which
cellular events that promote cell cycling and proliferation during
carcinogenesis are linked inextricably to stromal events that support
the expansion of abnormal cells thus driving tumour progression.
THERAPEUTIC IMPLICATIONS
Chemoprevention is the use of specific pharmacological or
nutrient agents to prevent, reverse or inhibit the process of
carcinogenesis. Recognition of the fact that many cancers have
distinct pre-invasive phases, combined with the realisation that a
number of these lesions appear to regress once the carcinogenic
stimulus is removed, suggests that it may be possible to prevent
the development of cancer. The discovery that angiogenesis and
carcinogenesis are linked and that angiogenesis is dependent for
growth has led to attempts to prevent carcinogenesis through
combined angiopreventive strategies (Albini et al, 2007). Although
traditional cancer chemoprevention relies on agents that prevent
or delay the transformation of normal cells into cancer cells,
angioprevention strategies target those cells in the microenviron-
ment associated with angiogenesis. These two interventions
targeting different cell types may act synergistically, resulting in
a more effective prophylaxis than can be achieved with either
individually. Advances in non-invasive imaging, facilitating the
assessment of angiogenesis in tissues, may allow clinicians to
monitor angiopreventive strategies (Barrett et al, 2007). Recent
research has demonstrated that statins promote endothelial cell
death and inhibit experimental angiogenesis induced by growth
factors, providing ‘proof of principle’ for developing statin-based
angiopreventive strategies (Boodhwani et al, 2006). Some flavo-
noids such as xanthohumol and deguelin have also been
demonstrated to have angiopreventive properties under experi-
mental conditions (Albini et al, 2007). These and the development
of newer angiopreventive compounds in future may offer the
ability to inhibit angiogenesis during pre-malignant stages and
delay the onset of, or progression to, cancer.
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